Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Sedatives and Hypnotics Drugs: Benzodiazepines01:19

Sedatives and Hypnotics Drugs: Benzodiazepines

1.2K
Benzodiazepines have both sedative and hypnotic properties. They include compounds such as diazepam (Valium) and alprazolam (Xanax). Structurally, their cores are similar, consisting of the fusion of a benzene ring and a diazepine ring, but they share a common mechanism of action in the central nervous system (CNS).
Benzodiazepines work by enhancing the effects of the inhibitory neurotransmitter GABA. They bind to the GABAA receptor, increasing its affinity for GABA, which opens chloride...
1.2K
CNS Depressants: Barbiturates and Benzodiazepines01:14

CNS Depressants: Barbiturates and Benzodiazepines

1.7K
CNS depressants include drugs from the category of barbiturates and benzodiazepines. They are valuable medications for managing anxiety disorders and insomnia. Barbiturates, once used to induce and maintain sleep, have been replaced mainly by benzodiazepines due to barbiturate's toxicity, tolerance, and overdose risks. They interact with GABAA receptors, leading to sedation at low doses and potentially coma and death at higher doses. Phenobarbital, a long-acting barbiturate, possesses...
1.7K
Sedatives and Hypnotics Drugs: Barbiturates01:20

Sedatives and Hypnotics Drugs: Barbiturates

1.3K
Sedatives and hypnotics encompass a drug class that acts on the central nervous system (CNS) to alleviate anxiety, promote relaxation and induce sleep.These drugs function by amplifying the actions of the neurotransmitter γ-aminobutyric acid (GABA), resulting in reduced neuronal activity. Barbiturates, a subset of sedatives and hypnotics first synthesized in the late 1800s, are categorized into ultra-short, short, intermediate, and long-acting groups based on their duration of effect. A...
1.3K
Anxiolytic Drugs: Benzodiazepines and Buspirone01:29

Anxiolytic Drugs: Benzodiazepines and Buspirone

3.0K
Benzodiazepines are a class of anxiolytic drugs known for their rapid efficacy and high therapeutic-to-lethal dose ratio, but with a potential risk of drug dependence. These drugs are lipophilic, allowing for rapid absorption after oral administration, eventually reaching the central nervous system (CNS). Once in the CNS, benzodiazepines bind to the allosteric site of the GABAA receptor. This binding enhances the inhibitory effects of the neurotransmitter GABA. By doing so, they prevent...
3.0K
Antiepileptic Drugs: GABAergic Pathway Potentiators01:18

Antiepileptic Drugs: GABAergic Pathway Potentiators

1.6K
γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
1.6K
Sedatives and Hypnotics Drugs: Miscellaneous Agents01:17

Sedatives and Hypnotics Drugs: Miscellaneous Agents

831
Sedatives and hypnotics encompass a wide range of substances, each with its unique mechanism of action, uses, and potential adverse effects.
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
831

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same authorSame journal

Corrected Version: Protection of Mice from Controlled Cortical Impact Injury by Food Additive Glyceryl Tribenzoate.

Journal of clinical & experimental immunology·2026
Same authorSame journal

Corrected Version: Sodium Benzoate, A Metabolite of Cinnamon and A Food Additive, Improves Cognitive Functions in Mice After Controlled Cortical Impact Injury.

Journal of clinical & experimental immunology·2026
Same author

PPARα and RXRα in the regulation of neuronal ceroid lipofuscinosis genes: implications for Batten disease therapy.

NeuroImmune pharmacology and therapeutics·2026
Same author

L-Leucine Upregulates Lysosomal Biogenesis and Autophagy to Lower Plaques in 5XFAD Mouse Model of Alzheimer's Disease.

Journal of neurochemistry·2026
Same author

RETRACTED: Rangasamy et al. Protection of Mice from Controlled Cortical Impact Injury by Food Additive Glyceryl Tribenzoate. <i>Int. J. Mol. Sci.</i> 2023, <i>24</i>, 2083.

International journal of molecular sciences·2026
Same author

RETRACTED: Rangasamy et al. Sodium Benzoate, a Metabolite of Cinnamon and a Food Additive, Improves Cognitive Functions in Mice After Controlled Cortical Impact Injury. <i>Int. J. Mol. Sci.</i> 2022, <i>23</i>, 192.

International journal of molecular sciences·2026
Same journal

Cinnamein Inhibits the Induction of Nitric Oxide and Proinflammatory Cytokines in Macrophages, Microglia and Astrocytes.

Journal of clinical & experimental immunology·2023
Same journal

Glyceryl tribenzoate: A food additive with unique properties to be a substitute for cinnamon.

Journal of clinical & experimental immunology·2021
Same journal

Can cinnamon spice down autoimmune diseases?

Journal of clinical & experimental immunology·2020
Same journal

A Novel Link between Early Life Allergen Exposure and Neuroimmune Development in Children.

Journal of clinical & experimental immunology·2020
See all related articles

Related Experiment Video

Updated: Mar 28, 2026

Controlled Cortical Impact Model for Traumatic Brain Injury
05:30

Controlled Cortical Impact Model for Traumatic Brain Injury

Published on: August 5, 2014

29.9K

Benzoate Drugs for Traumatic Brain Injury.

Swarupa Pahan1, Kalipada Pahan1,2

  • 1Division of Research and Development, Jesse Brown Veterans Affairs Medical Center, Chicago, USA.

Journal of Clinical & Experimental Immunology
|March 27, 2026
PubMed
Summary
This summary is machine-generated.

Sodium benzoate and glyceryl tribenzoate show potential in treating traumatic brain injury (TBI) pathologies in rodents. These FDA-approved compounds may offer new therapeutic avenues for TBI, a leading cause of death and disability.

Keywords:
Cognitive DysfunctionDrug RepurposingGlial ActivationGlyceryl TribenzoateNeurodegenerationNeuroprotectionOxidative StressSodium BenzoateTraumatic Brain Injury

More Related Videos

Assessing Changes in Synaptic Plasticity Using an Awake Closed-Head Injury Model of Mild Traumatic Brain Injury
09:49

Assessing Changes in Synaptic Plasticity Using an Awake Closed-Head Injury Model of Mild Traumatic Brain Injury

Published on: January 20, 2023

3.9K
A Novel In Vitro Model of Blast Traumatic Brain Injury
08:59

A Novel In Vitro Model of Blast Traumatic Brain Injury

Published on: December 21, 2018

11.3K

Related Experiment Videos

Last Updated: Mar 28, 2026

Controlled Cortical Impact Model for Traumatic Brain Injury
05:30

Controlled Cortical Impact Model for Traumatic Brain Injury

Published on: August 5, 2014

29.9K
Assessing Changes in Synaptic Plasticity Using an Awake Closed-Head Injury Model of Mild Traumatic Brain Injury
09:49

Assessing Changes in Synaptic Plasticity Using an Awake Closed-Head Injury Model of Mild Traumatic Brain Injury

Published on: January 20, 2023

3.9K
A Novel In Vitro Model of Blast Traumatic Brain Injury
08:59

A Novel In Vitro Model of Blast Traumatic Brain Injury

Published on: December 21, 2018

11.3K

Area of Science:

  • Neuroscience
  • Pharmacology
  • Toxicology

Background:

  • Traumatic brain injury (TBI) is a major cause of death and disability in the US.
  • TBI pathophysiology involves complex processes including neuroinflammation, BBB disruption, and neurodegeneration.
  • Currently, no specific treatments exist for TBI.

Purpose of the Study:

  • To evaluate the potential of sodium benzoate and glyceryl tribenzoate as therapeutic options for TBI.
  • To review recent studies on the efficacy of these benzoates in attenuating TBI pathologies in rodent models.

Main Methods:

  • Review of existing literature on the use of sodium benzoate and glyceryl tribenzoate in TBI models.
  • Analysis of the mechanisms by which these benzoates may mitigate TBI-related damage.

Main Results:

  • Recent studies suggest that sodium benzoate and glyceryl tribenzoate demonstrate potential efficacy in rodent models of TBI.
  • These compounds may help attenuate key pathological features of TBI.

Conclusions:

  • Sodium benzoate and glyceryl tribenzoate represent promising candidates for TBI therapeutic development.
  • Further research is warranted to explore their clinical applicability in human TBI patients.